SL Science Holding Ltd SLBT
SL Science Holding Ltd (Nasdaq: SLBT) is an oncology drug developer. Its lead program, CD-19 Armed-T Therapy, is in Pre-clinical for CD19+ blood cancers (Armed-T bispecific-antibody-conjugated immune cells). Its next catalyst on record is CD-19 Armed-T Therapy: Pre-IND meeting request (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CD-19 Armed-T Therapy — Pre-IND meeting request (Q1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CD-19 Armed-T Therapy | Blood cancers | cell therapy | Pre-clinical |
| Gamma Delta T (GDT) cell therapy | Pancreatic cancer | cell therapy | Pre-clinical |
| Gamma Delta T (GDT) cell therapy | Brain cancer (glioblastoma) | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.